On this page
Fulphila
pegfilgrastim-jmdb
351(k) Biosimilar
Overview
Source: Purple BookProprietary name
Fulphila
Proper name
pegfilgrastim-jmdb
Licence type
351(k) Biosimilar
BLA number
761075
Applicant
Biocon Biologics Inc.
Center
CDER
Presentations
1
First licensure
—
351(k) biosimilar pathway. This product was licensed as highly
similar to a reference product, with no clinically meaningful differences in
safety, purity or potency.
It is licensed as a biosimilar but is not designated interchangeable, so substitution requires the prescriber.
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 6MG/0.6ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | June 4, 2018 |
Reference product
Source: Purple BookThis product is licensed with reference to Neulasta (pegfilgrastim).
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |